Phase 1 study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

被引：14

作者：

Widemann, Brigitte C.

Marcus, Leigh Jessica

Fisher, Michael J.

Weiss, Brian D.

Kim, AeRang

Dombi, Eva

Baldwin, Andrea

Whitcomb, Patricia

Martin, Staci

Gillespie, Andrea

Doyle, Austin

机构：

[1] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA

[2] Childrens Natl Med Ctr, Washington, DC 20010 USA

[3] Childrens Hosp, Philadelphia, PA 19104 USA

[4] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

[5] NCI, Bethesda, MD 20892 USA

[6] NCI, Rockville, MD USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.10018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10018

引用

页数：1